Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Ralf Gutzmer, Daniil Stroyakovskiy, Helen J Gogas et al. · The Lancet · 2020

Cited by 662 works. doi:10.1016/s0140-6736(20)30934-x

Authors

References